(S)-4-(4-(methyl(2-(methylsulfonyl)ethyl)amino)-6-phenylpicolinamido)-5-oxo-5-(4-(hexyloxycarbonyl)piperazin-1-yl)pentanoic acid | 1188276-34-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-4-(4-(methyl(2-(methylsulfonyl)ethyl)amino)-6-phenylpicolinamido)-5-oxo-5-(4-(hexyloxycarbonyl)piperazin-1-yl)pentanoic acid
• 英文别名: (4S)-5-(4-hexoxycarbonylpiperazin-1-yl)-4-[[4-[methyl(2-methylsulfonylethyl)amino]-6-phenylpyridine-2-carbonyl]amino]-5-oxopentanoic acid
• CAS: 1188276-34-7
• 化学式: C₃₂H₄₅N₅O₈S
• 分子量: 659.804
• InChiKey: IAGNSWHCRLOSBJ-SANMLTNESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  46
• 可旋转键数：
  17
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  175
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 (S)-4-(4-(methyl(2-(methylsulfonyl)ethyl)amino)-6-phenylpicolinamido)-5-oxo-5-(4-(hexyloxycarbonyl)piperazin-1-yl)pentanoic acid
  参考文献：
  名称：

  Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation

  摘要：

  Polymer-assisted solution-phase (PASP) parallel library synthesis was used to discover a piperazinyl-glutamate-pyridine as a P2Y(12) antagonist. Exploitation of this lead provided compounds with excellent inhibition of platelet aggregation as measured in a human platelet rich plasma (PRP) assay. Pharmacokinetic and physiochemical properties were optimized leading to compound (4S)-4-[({4-[4-(methoxymethyl)piperidin-1-yl]-6-phenylpyridin-2-yl} carbonyl)amino]-5-oxo-5-{4-[(pentyloxy) carbonyl]piperazin-1-yl}pentanoic acid 22J with good human PRP potency, selectivity, in vivo efficacy and oral bioavailability. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.06.075